Oncotarget

Research Papers:

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients

Elodie Long-Mira, Marius Ilie _, Emmanuel Chamorey, Florence Leduff-Blanc, Henri Montaudié, Virginie Tanga, Maryline Allégra, Virginie Lespinet-Fabre, Olivier Bordone, Christelle Bonnetaud, Renaud Schiappa, Catherine Butori, Coraline Bence, Jean-Philippe Lacour, Véronique Hofman and Paul Hofman

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:36238-36249. https://doi.org/10.18632/oncotarget.26343

Metrics: PDF 1067 views  |   HTML 1495 views  |   ?  


Abstract

Elodie Long-Mira1,2,3,*, Marius Ilie1,2,3,*, Emmanuel Chamorey4, Florence Leduff-Blanc5, Henri Montaudié5, Virginie Tanga3, Maryline Allégra3, Virginie Lespinet-Fabre3, Olivier Bordone3, Christelle Bonnetaud3, Renaud Schiappa4, Catherine Butori1, Coraline Bence1, Jean-Philippe Lacour5, Véronique Hofman1,2,3 and Paul Hofman1,2,3

1Université Côte d’Azur, CHU Nice, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France

2Université Côte d’Azur, CNRS, INSERM, IRCAN, FHU OncoAge, Team 4, Nice, France

3Université Côte d’Azur, CHU Nice, FHU OncoAge, Hospital-Integrated Biobank, Nice, France

4Antoine Lacassagne Comprehensive Cancer Center, FHU OncoAge, Biostatistics Unit, Nice, France

5Université Côte d’Azur, CHU Nice, Department of Dermatology, Archet Hospital, Nice, France

*These authors contributed equally to this work

Correspondence to:

Marius Ilie, email: ilie.m@chu-nice.fr

Keywords: metastatic melanoma; BRAF; NRAS; cfDNA; IDYLLA™

Received: July 19, 2018     Accepted: November 01, 2018     Published: November 16, 2018

ABSTRACT

The mutation status of the BRAF and NRAS genes in tumor tissue is used to select patients with metastatic melanoma for targeted therapy. Cell-free circulating DNA (cfDNA) represents an accessible, non-invasive surrogate sample that could provide a snapshot of the BRAF and NRAS genotype in these patients.

We investigated the feasibility of the Idylla™ assay for detection of BRAF and NRAS mutations in cfDNA of 19 patients with metastatic melanoma at baseline and during the course of treatment. The cfDNA genotype obtained with Idylla was compared to the results obtained with matched-tumor tissue and to clinical outcome.

At baseline, 47% of patients harbored a BRAFV600 mutation in their cfDNA. Two months after targeted treatment the BRAFV600 mutant cfDNA was undetectable in all patients and 3 were disease-free. Moreover, 15% of patients harbored a NRAS mutation that was detected with plasma before treatment. The sensitivity and specificity were 80% and 89% for the BRAF status, and 79% and 100% for the NRAS status in pretreatment cfDNA compared to results obtained with a tissue test. Due to the small size of the population, no significant correlation was observed between the presence of BRAF or NRAS mutations in cfDNA and the metastatic tumor load or overall survival.

In conclusion, this study demonstrated that evaluation with the Idylla system of the BRAF and NRAS mutation status in cfDNA may be a surrogate for determination of the BRAF and NRAS status in tumor tissue.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26343